Literature DB >> 10335689

Predictors of sputum culture conversion among patients with tuberculosis in the era of tuberculosis resurgence.

Z Liu1, K L Shilkret, H M Ellis.   

Abstract

BACKGROUND: Sputum culture conversion among patients with tuberculosis (TB) is the most important indicator for the effectiveness of treatment and the infectivity of the disease. We sought to investigate predictors for documented sputum culture conversion among TB cases reported in the surveillance system.
METHODS: This study included 780 patients with pulmonary TB who were initially sputum culture positive in New Jersey in 1994-1995. These patients were followed up for at least 1 week and up to 1 year. Kaplan-Meier curves and Cox proportional hazards models were performed to analyze the data.
RESULTS: Overall, 469 (60.1%) of the 780 patients had documented sputum culture conversion. The elderly (36%) and non-Hispanic whites (41.3%) were the least likely to have documented sputum conversion. Patients who were initially given 4 or more drugs were 36% more likely to have documented sputum conversion than those who were initially given fewer than 4 drugs, after adjusting for other factors. Patients who were under the care of chest clinics and the model TB center were about 3 times more likely to have documented sputum conversion than those under care of private physicians. Sex, recurrent TB, foreign-born status, homelessness, injecting drug use, human immunodeficiency virus infection and drug-resistant TB were not significantly associated with the documentation of sputum culture conversion.
CONCLUSIONS: A substantial proportion of sputum culture-positive TB patients have no documented sputum culture conversion. The type of care provider was the predominant determinant for the documentation of sputum culture conversion.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10335689     DOI: 10.1001/archinte.159.10.1110

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  8 in total

1.  Anti-phospholipid antibody levels as biomarker for monitoring tuberculosis treatment response.

Authors:  Amador Goodridge; Carla Cueva; Maureen Lahiff; Grace Muzanye; John L Johnson; Payam Nahid; Lee W Riley
Journal:  Tuberculosis (Edinb)       Date:  2012-03-10       Impact factor: 3.131

2.  Factors influencing sputum smear conversion at one and two months of tuberculosis treatment.

Authors:  Sumant Pajankar; Rajiv Khandekar; Musallam Amer Al Amri; Mohammed Redha Al Lawati
Journal:  Oman Med J       Date:  2008-10

3.  Smear microscopy and culture conversion rates among smear positive pulmonary tuberculosis patients by HIV status in Dar es Salaam, Tanzania.

Authors:  Mbazi Senkoro; Sayoki G Mfinanga; Odd Mørkve
Journal:  BMC Infect Dis       Date:  2010-07-16       Impact factor: 3.090

4.  Rethinking the socioeconomics and geography of tuberculosis among foreign-born residents of New Jersey, 1994-1999.

Authors:  Amy L Davidow; Bonita T Mangura; Eileen C Napolitano; Lee B Reichman
Journal:  Am J Public Health       Date:  2003-06       Impact factor: 9.308

5.  Tuberculosis treatment managed by providers outside the Public Health Department: lessons for the Affordable Care Act.

Authors:  Melissa Ehman; Jennifer Flood; Pennan M Barry
Journal:  PLoS One       Date:  2014-10-23       Impact factor: 3.240

Review 6.  Adjuvant Efficacy of Nutrition Support During Pulmonary Tuberculosis Treating Course: Systematic Review and Meta-analysis.

Authors:  Zhuang-Li Si; Ling-Ling Kang; Xu-Bo Shen; Yuan-Zhong Zhou
Journal:  Chin Med J (Engl)       Date:  2015-12-05       Impact factor: 2.628

7.  Treatment of Active Tuberculosis in Chicago, 2008-2011: The Role of Public Health Departments.

Authors:  Reid Fletcher; Joshua D Jones; Neha S Shah
Journal:  PLoS One       Date:  2016-10-12       Impact factor: 3.240

8.  Therapeutic effects of recombinant human interleukin 2 as adjunctive immunotherapy against tuberculosis: A systematic review and meta-analysis.

Authors:  Ruimei Zhang; Xiangyu Xi; Chunying Wang; Yong Pan; Changhua Ge; Liying Zhang; Shuo Zhang; Huimei Liu
Journal:  PLoS One       Date:  2018-07-19       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.